Cellectis S.A. (ALCLS.PA)

EUR 1.56

(-2.14%)

Market Cap (In EUR)

112.17 Million

Revenue (In EUR)

755 Thousand

Net Income (In EUR)

-101.05 Million

Avg. Volume

46.5 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.534-3.25
PE
-
EPS
-
Beta Value
3.2
ISIN
FR0010425595
CUSIP
F1775Q107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Andre Choulika Ph.D.
Employee Count
-
Website
https://www.cellectis.com
Ipo Date
2007-02-07
Details
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.